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The main goal of this study was to investigate whether lidamycin (LDM) could enhance the efficacy of paclitaxel (TAX) against 
breast cancer. In the MTT assay, LDM showed much more potent cytotoxicity than paclitaxel, and there was a synergy on the 
4T1/luc breast cancer cells treated with a combination of paclitaxel and LDM. Western blot analysis showed that paclitaxel and 
LDM synergistically downregulated MMP9, MMP2, VEGF, and upregulated the cleaved PARP proteins. By wound closure cell 
migration assay, paclitaxel combined LDM obviously inhibited the migration of 4T1/luc cells. At therapeutic dosage level, LDM, 
paclitaxel, and the combination suppressed the pulmonary metastases by 70.2%, 53.8%, and 88.7%, respectively, and the CDI 
value was 0.82, indicating synergism. The results show that LDM enhances the antitumor effect of paclitaxel on 4T1/luc breast 
cancer, in particular, the antimetastatic effects on pulmonary metastasis.  
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Breast cancer has been the second leading cause of can-
cer-related mortality among women throughout the world 
[1]. Surgery is still the mainstay of treatment for primary 
breast cancer, but is ineffective for metastatic tumors at dis-
tant sites, and it may paradoxically increase the dissemina-
tion of tumor cells into the bloodstream resulting in the 
seeding of tumor cells in distant organs [2,3]. Adjuvant 
chemotherapy for breast cancer after surgery has been the 
standard of care, and can effectively prevent the occurrence 
of tumor cell dissemination and metastasis. Paclitaxel (Tax-
ol, TAX) has been proved to be a potent drug to treat meta-
static breast cancer, ovarian cancer, and other forms of can-
cer [4]. It blocks the cell cycle in the G2 and M phase by 
preventing polymerization of microtubules, thereby causing 
toxicity and cell death [5]. Paclitaxel is active in the treat-
ment of metastatic breast cancer as first-line therapy [6], as 
well as in heavily pretreated patients [7,8]. Especially en-
couraging is its activity in anthracycline-resistant disease 
[9]. However, several toxic side effects and clinical impli-
cations, including severe anaphylactic peripheral neuropa-
thy and hypersensitivity reactions, have been reported in 
paclitaxel-treated patients. Therefore, potential therapeutic 
strategies to improve the efficacy of paclitaxel and reducing 
its side effects are needed. 
Anticancer antibiotic lidamycin (LDM, C-1027) was 
screened from the broth filtrate of Streptomyces globisporus 
C-1027 by spermatogonial assay. Strain C-1027 was isolat-
ed from a soil sample collected in Qianjiang area, Hubei 
Province of China [10]. LDM belongs to a family of ene-
diyne antibiotics and shows extremely potent cytotoxicity 
by causing DNA double-strand breaks. LDM also markedly 
inhibits the growth of transplantable tumors in vivo [11–13]. 
LDM has demonstrated unique characteristics in the treat-
ment of cancer, such as preferentially targeting hypoxic 
cells, dosage-dependent regimens based upon p53 status, 
and high activity against multidrug-resistant cancer cells 
[14–16]. LDM is now in phase II clinical trials as a potential 
chemotherapeutic agent in China. 
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Recent study revealed that LDM combined with other 
anticancer drugs can effectively enhance the antitumor ac-
tivity [17,18]. In this study, the highly metastatic 4T1 breast 
cancer model was used. As well known, the 4T1 cell line 
was derived from a spontaneously arising BLAB/c mam-
mary tumor. It grows progressively and causes a uniformly 
lethal disease even after excision of the primary tumor [19]. 
4T1 tumor metastasizes via the hematogenous route to the 
liver, lungs, bone, and the brain. It closely resembles stage 
IV human breast cancer both in its immunogenicity, growth 
and metastatic properties, making it an excellent animal 
model to evaluate the effects of drugs on breast tumor me-
tastases as well as tumor growth [20–22]. Herein, we inves-
tigated whether the combination of LDM with paclitaxel 
would enhance the antitumor and antimetastatic activity to 
combat the highly metastatic 4T1 breast cancer in vitro and 
in vivo. 
1  Materials and methods 
1.1  Cell culture 
The mouse breast cancer cell line 4T1 was purchased from 
ATCC (ATCC number CRL-2539), and the cell line 4T1/ 
luc was constructed by stable expression of firefly luciferase. 
The 4T1/luc cells showed an equivalent metastatic potential 
with the parental 4T1 cells. The cells were cultured in 
RPMI-1640 (Gibco, USA) supplemented with 10% FBS 
(Gibco), 100 U mL−1 penicillin, and 100 μg mL−1 strepto-
mycin, 2 mmol L−1 L-glutamine and 400 μg mL−1 G418 in a 
humidified atmosphere of 5% CO2 in air. 
1.2  Transfection and selection of stably transfected 
4T1/luc cells 
4T1/luc cells at 70%–80% confluence were transfected with 
1 μg of luciferase expression plasmid PCAGGS-NEO-luc 
using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) 
according to the manufacturer’s instructions. For stable 
transfection, the cells were exposed to 500 μg mL−1 G418 
(Gibco) after transfection 1 day later. After growth for 3 
weeks, cells were plated at a lower density in RPMI- 1640 
with 500 μg mL−1 G418 and 10% FBS in 96-wells plates 
until single colony was formed. Single cloned cells were 
isolated and expanded. To identify the positive clones, 
monoclonal cells were plated in 96-well plates and lucifer-
ase substrate D-luciferin was added to a final concentration 
of 60 mg mL−1. After 30 min of exposure, the fluorescence 
intensity of expression was examined with the optical im-
aging system (IVIS 200, Xenogen) and the most fluorescent 
clone was selected and cryopreserved. 
1.3  Luciferase activity test of 4T1/luc cells in vitro 
The 4T1/luc cells were diluted in 96 well plates at a density 
of 6000, 3000, 1500, 750, 300, 150, and 75 cells per well, 
respectively, and the cells were exposed to the fluorescent 
luciferase substrate D-luciferin. The luminous intensity was 
detected in the camera box by IVIS-Imaging System. 
1.4  Cell viability assay 
Cell viability was evaluated by using the MTT assay. 
4T1/luc cells were seeded in 96-well plates (Costar, USA) 
at a density of 3×103 cells/well in 200 μL medium. The next 
day cells in triplicate wells were treated with LDM (10−14, 
10−13, 10−12, 10−11, 10−10, 10−9, 10−8, 10−7 mol L−1), paclitaxel 
(10−11, 10−10, 10−9, 10−8, 10−7, 10−6, 10−5, 10−4 mol L−1), or 
the combination of the two agents. After drug exposure for  
48 h, 20 μL MTT solutions (5 mg mL−1) were added to each 
plate. After being incubated at 37°C for another 4 h, the 
formazan, which is derived from MTT by living cells, was 
dissolved in 150 μL per well of DMSO, and the absorbance 
was detected at 570 nm. The percentage of cell viability was 
calculated as follows: cell viability (%) = (OD570 of experi-
mental well-OD570 of blank)/(OD570 of control well-OD570 of 
blank). The IC50 (defined as the drug concentration with 
which 50% cell growth was inhibited) was assessed from 
the dose-response curves. All MTT experiments were per-
formed in triplicate and repeated at least 3 times. 
1.5  Western blot analysis 
Cells treated with LDM (0.01 nmol L−1), paclitaxel (10 
nmol L−1) and the combination of both agents for 48 h were 
lysed in RIPA buffer on ice and then centrifuged at 12000  
r min−1 for 10 min at 4°C to collect the supernatant. Protein 
concentrations were determined using BCA reagent (Pierce, 
USA). Protein samples were separated by 12% SDS-PAGE 
and than transferred to a polyvinylidene membrane. After 
incublated overnight at 4°C in 1% BSA-PBST(phosphate 
buffered saline contained 0.1% Tween 20), the membranes 
were incublated with primary and secondary antibodies, 
band intensity was detected by chemiluminescence using 
ECL detection reagents (Millipore, USA). Blots were 
stained with an anti-β-actin to confirm that each lane con-
tained similar amounts of tumor homogenate. 
1.6  Wound closure cell migration assay 
4T1/luc cells were seeded in a 6-well plate and incublated 
24 h to allow for confluency. A 10 μL pipette tip was then 
used to create a wound through the center of the confluent 
cell layer, and the size of the wound was measured. Cells 
were then treated with 3 mL LDM (0.01 nmol L−1), 
paclitaxel (10 nmol L−1) and the combination of both agents 
for 24 h. Photos were taken of the wound periodically 
throughout the assay. To quantify the changes, the size of 
the wound was measured again after 24 h. This analysis 
gave the distance (μm) that tumor cells migrated.  
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1.7  Animal experiments 
The 6–8-week-old female BALB/c mice were purchased 
from the Institute of laboratory Animal Sciences, Chinese 
Academy of Medical Sciences & Peking Union Medical 
College. 4T1/luc cells in log phase were suspended to a 
final concentration of 5.0×106 cells mL−1 with phosphate- 
buffered saline (PBS), and 5.0×105 4T1/luc cells in 0.1 mL 
were injected into the second mammary fatpad. Primary 
tumors were measured every 3 days. When tumors reached 
about 400 mm3 in size, the mice were randomized divided 
into four groups (n = 10 per group). Then the treatment 
were started, the mice were injected intravenously with 
LDM (0.05 mg kg−1), intraperitoneally with paclitaxel     
(5 mg kg−1), and the combination of LDM (0.05 mg kg−1) 
plus paclitaxel (5 mg kg−1). LDM and paclitaxel were in-
jected once a week and last for two weeks. Control group 
was injected with saline. Tumor growth was measured with 
a vernier caliper, and tumor volumes were calculated with 
the following formula: V = 0.5a × b2, where a and b are the 
long and the perpendicular short diameters of the tumors, 
respectively. At day 30, all mice were weighed and sacri-
ficed, and tumors were excised. Tumors were weighed, and 
the mean tumor weight was calculated. Tumor growth inhi-
bition was calculated by the following formula: [(C−T)/C] 
×100 (C, tumor weight of control; T, tumor weight of treat-
ed group). The lungs were removed, and fixed in formalin 
overnight before evaluation of lung metastasis. The number 
of lung metastases on the lung surface was counted with a 
magnifying lens. 
The tumor growth inhibitory effect was estimated using 
the treated/control ratio (T/C). In order to calculate the coef-
ficient of drug interaction (CDI), the following equation 
was used: CDI=AB/A ×B, where A or B was the mean T/C 
of drug A and drug B respectively, and AB was the mean 
T/C of drug A combined with drug B. A CDI greater than 1 
indicates antagonism, a CDI equal to 1 indicates additive 
and a CDI less than 1 indicates synergy. 
1.8  Optical imaging and histological analysis  
At day 30, before sacrificed the mice, an optical molecular 
imaging system was used to evaluate the growth of primary 
tumor. Luciferase substrate D-luciferin (150 mg kg−1) was 
injected intraperitoneally, and the animals were placed onto 
the warmed stage inside the camera box of IVIS-Imaging 
System (Xenogen) to observe the tumor and the lungs from 
different groups. Tissues were fixed in 4% paraformalde-
hyde in PBS, embedded in paraffin and cut into 3–5 μm 
sections through the center of the tissue specimen. Then the 
sections were stained with hematoxylin and eosin (H & E). 
Stained sections were observed using a microscope. 
1.9  Statistics  
The results were presented as the mean±SD. A one-way 
analysis of variance was carried out for multiple compari-
sons. If there was significant variation between treatment 
and control groups, the mean values were compared by us-
ing Student’s t-test. P-values less than 0.05 were considered 
statistically significant. 
2  Results 
2.1  Luciferase activity in 4T1/luc cells 
The bioluminescence photon is positively correlated to the 
number of cells (Figure 1). The minimum detectable cell 
number was 750 cells per well according to our results. 
2.2  Effect of LDM in combination with paclitaxel on 
the growth of 4T1/luc breast cells in vitro 
Dose-response growth inhibitory effects were observed in 
the MTT assay, and a significant reduction in growth was 
observes in cells treated with LDM plus paclitaxel com-
pared to cells treated with LDM or paclitaxel alone (Figure 
2). And the IC50 values of LDM and paclitaxel for 4T1/luc 
cell were 4.61×10−1 and 3.30×102 nmol L−1, respectively. 
LDM showed about 1000-fold much more potent cytotoxi-
city than paclitaxel. 
2.3  Western blot analysis  
Western blot analysis was used to detect the metastasis- 
related and apoptosis-related proteins. As shown, the me- 
 
 
Figure 1  The positive correlation between the photons of bioluminescence and the numbers of 4T1/luc cells. 
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Figure 2  Effect of LDM and paclitaxel on cell viability in 4T1/luc cells. (a) 4T1/luc cancer cells were treated with LDM and paclitaxel alone at concentra-
tions ranging from 10−5 to 105 nmol L−1 for 48 h. (b) and (c) 4T1/luc cells were treated with LDM combined paclitaxel at different concentrations for 48 h. 
tastasis-related proteins MMP9, MMP2, VEGF were down-
regulated, and the combination treatment had a more obvi-
ous down-regulation (Figure 3). The 89 kD cleaved frag-
ment of PARP increased after treated. A markedly enhanced 
effect was observed in the combination group. 
2.4  Wound closure cell migration assay 
To examine the effects of LDM, paclitaxel and the combi-
nation on tumor cell migration, the cell wound closure assay 
was performed. In the wound closure assay (Figure 4), the 
combined group showed a significant (P<0.001) inhibition 
of cell migration, compared to the LDM group and paclitaxel 
group. 
2.5  Animal experiment 
Antitumor and antimetastatic experiments were performed 
with mouse mammary carcinoma 4T1/luc cell in BALB/c 
mice. In this study, 4T1/luc tumors were growing rapidly in 
control group in 30 d during the experiment (Figure 5(a)), 
and the body weight of each group was recorded (Figure 
5(b)). As evaluated on day 30 (Table 1), the LDM and 
paclitaxel group showed therapeutic efficacy with 38.3% 
and 36.5% TGI, respectively, and the combination group 
showed higher therapeutic efficacy with 64.2% TGI for the 
primary tumor. The CDI value of LDM and paclitaxel was 
 
 
Figure 3  The Western blot analysis of metastasis-related and apoptosis- 
ralated proteins. 
0.91, indicating synergism. 
The therapeutic efficacy against metastases was evaluat-
ed at day 30 when mice were sacrificed. Lungs were care-
fully examined. The tumor nodules on the lungs were 
counted under the dissecting microscope (Figure 6(a) and 
(c)). Photos of the lungs were taken by IVIS-Imaging Sys-
tem (Figure 6(b) and the pathological changes were ob-
served on sections by HE staining (Figure 6(d)). The com-
bined group significantly reduced the number of lung me-
tastases (Figure 6(b)). The inhibition rates of metastases by 
LDM, paclitaxel, and the combination of them were 70.2%, 
53.8%, and 88.7%, respectively, and the CDI value was 
0.82, indicating synergism.  
3  Discussion 
Metastasis is the most lethal attribute of breast cancer. Once 
breast cancer metastasizes to distant areas of the body, typ-
ically the lung, bones, liver, and central nervous system, it 
can be treated but is essentially not curable [23]. The 4T1 
cell line is widely considered to be one of the best mouse 
mammary cancer cell lines for the study of human cancer 
progression [24,25]. This tumor shares many characteristics 
with human mammary cancers, it closely resembles stage 
IV human breast cancer, making it an excellent animal 
model. It was used to investigate inhibitors of DNA-binding 
proteins necessary for cancer stem cells [26], chemo-
resistance [27], antimetastatic activities of various drugs and 
drug combination [28,29]. 4T1/luc cells were engineered for 
stable expression of firefly luciferase to allow tracking and 
quantifying of the cells in vivo. 
As an enediyne anticancer antibiotic, LDM showed ex-
tremely potent cytotoxicity toward cultured cancer cells and 
markedly inhibited the growth of transplantable tumors in 
mice [30–32]. LDM (C1027) also showed antiangiogenesis 
and antimetastatic activity, preferentially targeting hypoxic 
cells [14]. In the previous study, it has been studied for 
cancer treatment, enhancement of its targeting, selectivity 
and efficiency, and drug combination therapy of certain 
cancers [33–35]. As reported, LDM induced unusual DNA 
double-strand breaks [36]. It could induce apoptosis or mi-
totic cell death and alter cell cycle progression in many   






Figure 5  Antitumor activities of LDM, paclitaxel alone or both of them on 4T1/luc breast cancer model. The tumor growth curves (a) and body growth 
curves (b) in 30 d duration of experiments. Data are expressed as mean ±SD (n=10). (c) Optical imaging in living animal. Color scale represents photons     
s−1 cm−2 steradian−1, the red dot-cycle indicated the tumor location. * P<0.05 compared to control, ** P<0.01 compared to control, *** P<0.001 compared to 
control. 
Figure 4  The effects of LDM and paclitaxel 
on 4T1/luc tumor cell migration in the wound 
closure assays. (a) Micrographs of 4T1/luc 
breast cancer cell wound closure; (b) quantifi-
cation of 4T1/luc breast cancer cell wound 
closure. The extent of wound closure was 
quantified by measuring the distances (μm) 
between the wounds after 24 h. *P<0.05 com-
pared to control, ** P<0.01 compared to con-
trol, *** P<0.001 compared to control. 
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Table 1  The growth inhibition of mouse mammary carcinoma 4T1/luc primary tumor in BALB/c mice 

























Figure 6  The antimetastatic effect of LDM, paclitaxel, and the combination. (a) Representative photos of the lungs from different groups; (b) optical im-
aging of lungs from different groups. Color scale represents photons s−1 cm−2 steradian−1. (c) Metastatic nodules on the lung surface. The number of macro-
scopic metaststic nodules was observed on the lung surface of treated mice killed on day 30 (n=10). Each data point represents the value for an individual 
animal. Solid bars represent the mean value for each treatment groups. (d) The pathological changes of lungs by H.E. staining were observed with light mi-
croscope (×100). 
cancer cells [37]. So far, there are no reports describing the 
combined efficacy of paclitaxel plus LDM on the antitumor 
and antimetastatic activities with a breast cancer animal 
model with highly metastatic potential. 
In this study, LDM combined paclitaxel exhibited potent 
antitumor and antimetastatic effects against the highly met-
astatic mouse 4T1/luc breast cancer without obvious sys-
temic toxicity. LDM combined paclitaxel resulted an ap-
proximately 30% higher inhibition rate in tumor growth 
compared to that of LDM, paclitaxel alone. The reduction in 
lung metastases might be due to: (1) LDM and paclitaxel 
significantly suppressing the growth of the primary tumors. 
Smaller and less viable primary tumors would beat less risk 
of dissemination. (2) LDM and paclitaxel directly prevent-
ing the formation of the lung metastases. To our knowledge, 
this is the first report of detection of LDM and paclitaxel 
combination effected on a metastatic mouse breast cancer 
model. Evidently, with the construction of the stable ex-
pression of firefly luciferase 4T1/luc cell lines, we can 
monitor and quantitatively analyze the tumor growth and 
metastasis simply and directly. 
In conclusion, LDM or paclitaxel alone exerts antitumor 
and antimetastatic activity in the highly metastatic mouse 
breast cancer model. The combination of LDM and pa- 
clitaxel synergistically enhances the antitumor and anti-
metastatic efficacy. 
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